Skip to main content

Charles River Laboratories income statement

  • CRL · NYSE
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$337.97−0.83%Close 13 Nov 2026 · Market value $16.04B

Charles River Laboratories reported revenue of $4.02 billion for fiscal year 2025 (the twelve months to 27 Dec 2025), down 0.9% from fiscal 2024. Net income was −$144 million and diluted earnings per share −$2.91.

From Charles River Laboratories's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 27 Dec 2025. TTM is the last four reported quarters added up.

Annual

Charles River Laboratories income statement, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$1.30B$1.17B$1.13B$1.14B$1.13B$1.17B$1.30B$1.36B$1.68B$1.86B$2.27B$2.62B$2.92B$3.54B$3.98B$4.13B$4.05B$4.02B$3.98B
Revenue growth—−9.5%−3.3%+0.8%−1.1%+3.2%+11.3%+5.1%+23.3%+10.5%+22.0%+15.7%+11.5%+21.1%+12.3%+3.9%−1.9%−0.9%—
Cost of revenue$252.9M$255.7M$253.0M$268.0M$257.7M$272.8M$266.4M$264.0M$277.0M$289.7M—$1.66B$1.85B$2.21B$2.51B$2.63B$2.72B$2.69B$2.65B
Gross profit$1.04B$916.0M$880.5M$874.7M$871.8M$892.8M$1.03B$1.10B$1.40B$1.57B—$958.3M$1.07B$1.33B$1.46B$1.50B$1.33B$1.32B$1.33B
Gross margin80.5%78.2%77.7%76.5%77.2%76.6%79.5%80.6%83.5%84.4%—36.6%36.7%37.7%36.8%36.4%32.9%33.0%33.3%
Selling, general and administrative$223.9M$227.7M$232.5M$198.6M$208.2M$225.7M$269.0M$300.4M$364.7M$371.3M$443.9M$517.6M$528.9M$619.9M$665.1M$747.9M$751.0M$743.1M$725.0M
Operating income−$451.8M$169.6M−$298.5M$174.3M$165.8M$151.4M$177.7M$206.4M$237.6M$288.3M$331.4M$351.2M$432.7M$589.9M$651.0M$617.3M$227.3M$25.16M$159.0M
Operating margin−34.9%14.5%−26.3%15.3%14.7%13.0%13.7%15.1%14.1%15.5%14.6%13.4%14.8%16.7%16.4%14.9%5.6%0.6%4.0%
Interest expense$22.34M$21.68M$35.28M$42.59M$33.34M$20.97M$11.95M$15.07M$27.71M$29.78M$63.77M$60.88M$86.43M$73.91M$59.29M$136.7M$126.3M$107.0M$109.4M
Income before tax−$471.4M$151.6M−$334.1M$132.7M$129.7M$138.3M$177.6M$195.4M$222.9M$297.0M$281.7M$304.1M$447.1M$480.7M$623.0M$581.3M$93.11M−$99.50M−$100.2M
Income tax expense$57.03M$40.35M$23.00K$17.14M$27.63M$32.91M$47.67M$43.39M$66.83M$171.4M$54.46M$50.02M$81.81M$81.87M$130.4M$100.9M$67.82M$42.66M−$142.8M
Effective tax rate−12.1%26.6%0.0%12.9%21.3%23.8%26.8%22.2%30.0%57.7%19.3%16.5%18.3%17.0%20.9%17.4%72.8%−42.9%143%
Net income−$524.5M$114.4M−$336.7M$109.6M$97.30M$102.8M$126.7M$149.3M$154.8M$123.4M$226.4M$252.0M$364.3M$391.0M$486.2M$474.6M$22.20M−$144.3M$40.19M
Net margin−40.5%9.8%−29.7%9.6%8.6%8.8%9.8%11.0%9.2%6.6%10.0%9.6%12.5%11.0%12.2%11.5%0.5%−3.6%1.0%
Net income to common shareholders—$114.4M−$336.7M$109.6M$97.30M$102.8M$126.7M$149.3M——————$486.2M$474.6M$10.30M−$144.3M—
EPS · diluted−$7.80$1.74−$5.38$2.14$2.01$2.12$2.66$3.13$3.23$2.54$4.62$5.07$7.20$7.60$9.48$9.22$0.20−$2.91$0.83
Diluted weighted average shares67.2M65.6M62.6M51.3M48.4M48.5M47.6M47.6M48.0M48.6M49.0M49.7M50.6M51.4M51.3M51.5M51.6M49.6M48.7M
Basic weighted average shares—65.4M62.6M50.8M47.9M47.7M46.6M46.5M47.0M47.5M47.9M48.7M49.5M50.3M50.8M51.2M51.4M49.6M48.5M
EBITDA−$365.0M$259.6M−$204.9M$259.5M$247.0M$248.0M$274.1M$301.3M$364.2M$419.4M$493.2M$549.2M$667.7M$855.4M$954.8M$931.4M$589.1M$428.5M$444.0M
EBITDA margin−28.2%22.2%−18.1%22.7%21.9%21.3%21.1%22.1%21.7%22.6%21.8%21.0%22.8%24.2%24.0%22.6%14.5%10.7%11.2%
Depreciation & amortization$86.85M$89.96M$93.65M$85.23M$81.28M$96.64M$96.44M$94.88M$126.7M$131.2M$161.8M$198.1M$234.9M$265.5M$303.9M$314.1M$361.7M$403.3M$285.0M
Stock-based compensation$24.21M$23.65M$25.53M$21.71M$21.86M$24.54M$31.04M$40.12M$43.64M$44.00M$47.35M$57.27M$56.34M$71.47M$73.62M$72.05M$69.89M$71.08M$80.56M

Quarterly

Charles River Laboratories income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$1.01B$1.01B$1.03B$1.01B$1.00B$984.2M$1.03B$1.00B$994.2M$995.8M$1.00B$982.7M
Cost of revenue$649.4M$666.7M$672.4M$660.7M$718.3M$666.4M$675.1M$666.1M$684.5M$701.2M$640.7M$624.9M
Gross profit$364.1M$344.8M$353.7M$349.0M$284.2M$317.7M$357.1M$338.8M$309.7M$294.7M$363.4M$357.9M
Gross margin35.9%34.1%34.5%34.6%28.4%32.3%34.6%33.7%31.1%29.6%36.2%36.4%
Selling, general and administrative$197.1M$186.3M$169.8M$199.2M$195.7M$177.8M$191.5M$177.6M$196.1M$159.4M$228.9M$140.6M
Operating income$132.9M$126.0M$151.7M$117.4M−$167.7M$74.67M$100.1M$133.8M−$283.4M$119.9M$119.9M$202.6M
Operating margin13.1%12.5%14.8%11.6%−16.7%7.6%9.7%13.3%−28.5%12.0%11.9%20.6%
Interest expense$33.54M$35.00M$32.77M$30.28M$28.23M$27.88M$29.97M$25.40M$23.77M$26.74M$30.34M$28.52M
Income before tax$208.7M$99.01M$119.7M$91.24M−$216.8M$35.98M$71.42M$87.20M−$294.1M−$29.94M$53.17M$170.7M
Income tax expense$19.75M$24.53M$25.39M$20.95M−$3.04M$10.10M$18.73M$31.64M−$17.81M−$15.14M$53.93M−$163.8M
Effective tax rate9.5%24.8%21.2%23.0%1.4%28.1%26.2%36.3%6.1%50.6%101%−96.0%
Net income$187.1M$72.96M$94.08M$69.66M−$214.5M$25.47M$52.33M$54.42M−$276.6M−$14.84M−$1.48M$333.1M
Net margin18.5%7.2%9.2%6.9%−21.4%2.6%5.1%5.4%−27.8%−1.5%−0.1%33.9%
Net income to common shareholders$187.1M$67.33M$89.99M$68.68M−$215.7M$25.47M$52.33M$54.42M−$276.6M———
EPS · diluted$3.65$1.30$1.74$1.33−$4.20$0.50$1.06$1.10−$5.62−$0.30−$0.03$6.86
Diluted weighted average shares51.3M51.8M51.8M51.6M51.4M50.9M49.3M49.4M49.2M49.0M48.0M48.6M
Basic weighted average shares51.3M51.4M51.6M51.4M51.1M50.7M49.1M49.2M49.2M49.0M48.0M47.8M
EBITDA$213.4M$211.3M$237.7M$205.6M−$65.58M$195.0M$219.6M$219.0M−$205.2M$187.0M$187.2M$274.9M
EBITDA margin21.1%20.9%23.2%20.4%−6.5%19.8%21.3%21.8%−20.6%18.8%18.6%28.0%
Depreciation & amortization$80.51M$85.36M$86.08M$88.20M$102.1M$120.4M$119.5M$85.16M$78.28M$67.15M$67.29M$72.26M
Stock-based compensation$19.52M$16.74M$16.59M$19.33M$17.23M$13.13M$17.05M$23.27M$17.63M$22.38M$19.78M$20.77M

The main figures as JSON and plain text. See data and methodology.

CRL in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.